Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Artrya Limited ( (AU:AYA) ) has issued an update.
Artrya Limited has secured in-principle participation from HCA Midwest Health in its upcoming retrospective, multi-centre SAPPHIRE Study in the United States, pending protocol and ethics approval. The inclusion of HCA Midwest Health, a high-volume cardiology provider in Kansas City led locally by advanced imaging specialist Dr Stephen Bloom, expands the geographic reach and clinical depth of the study, which is designed to evaluate the prognostic and clinical utility of Artrya’s Salix Plaque Analysis and Plaque Dispersion Score in identifying high-risk coronary artery disease patients more precisely than traditional risk models, potentially strengthening Artrya’s clinical evidence base and positioning in the U.S. cardiovascular imaging market ahead of the study’s planned 2026 launch.
The most recent analyst rating on (AU:AYA) stock is a Hold with a A$4.00 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited (ASX: AYA) is an Australian medical technology company focused on AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary Salix cloud platform analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians with more accurate and efficient diagnosis, and the company is progressing regulatory and commercial activities in key international markets.
Average Trading Volume: 793,994
Technical Sentiment Signal: Buy
Current Market Cap: A$646.6M
Find detailed analytics on AYA stock on TipRanks’ Stock Analysis page.